KYMR Q4 2020 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M+597.5% YoY

Gross Profit

$13M100.0% margin

Operating Income

-$13M-100.0% margin

Net Income

-$13M-99.2% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-12.0%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$22M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$487M

Total Liabilities

$203M

Stockholders' Equity

$284M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$2M	+597.5%
Gross Profit	$13M	$2M	+597.5%
Operating Income	-$13M	-$12M	-8.5%
Net Income	-$13M	-$12M	-10.2%